oxazoles has been researched along with Fatty Liver, Nonalcoholic in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 7 (63.64) | 2.80 |
| Authors | Studies |
|---|---|
| Alkhouri, N; Balendran, C; Billin, AN; Buchholtz, K; Damgaard, LH; Hassanein, T; Herring, R; Huss, RS; Kabler, H; Kayali, Z; Kjær, MS; Kohli, A; Loomba, R; Myers, RP; Noureddin, M; Zhu, Y | 1 |
| Katsiki, N; Polyzos, SA | 1 |
| Aoyama, K; Erion, DM; Kaneko, M; Matsumoto, M; Nakamura, S; Nambu, T; Nishida, M; Ogino, H; Wang, X; Yashiro, H | 1 |
| Attia, SL; Mouzaki, M; Softic, S | 1 |
| Alkhouri, N; Beck, AH; Bhandari, BR; Borg, BB; Caldwell, SH; Chuang, JC; Chung, C; Ding, D; Elkhashab, M; Ghalib, R; Goodman, Z; Gunn, N; Hassanein, T; Huss, RS; Iyer, R; Jia, C; Kabler, H; Kohli, A; Kowdley, KV; Loomba, R; Myers, RP; Neff, G; Noureddin, M; Patel, K; Poulos, J; Resnick, M; Ruane, P; Sheikh, A; Shiffman, ML; Strasser, S; Subramanian, GM; Wapinski, I; Wong, VW; Younes, Z | 1 |
| Cai, D; Guo, F; Holm, L; Li, Y; Liu, HY; Zhang, K; Zhou, B | 1 |
| Cheng, LH; Cui, S; Ge, CL; Guo, YT; Hao, HP; He, QX; Pan, XJ; Wang, GJ; Wang, H; Yan, TT; Zhang, PF; Zhou, JY | 1 |
| Alkhouri, N; Chung, C; Coste, A; Fitch, M; Han, L; Hellerstein, M; Lawitz, EJ; Li, K; Loo, N; Loomba, R; McColgan, BJ; McHutchison, JG; Middleton, MS; Myers, RP; Nguyen, T; Nyangau, E; Poordad, F; Ray, AS; Sirlin, C; Subramanian, GM; Tarrant, JM | 1 |
| Bennett, M; Charlton, M; Chung, C; Harrison, SA; Harting, E; Kayali, Z; Lai, M; Lawitz, EJ; Loomba, R; McColgan, BJ; Middleton, MS; Myers, RP; Noureddin, M; Ray, AS; Ruane, P; Subramanian, GM; Tarrant, JM; Wang, L | 1 |
| Anthérieu, S; Claude, N; de la Moureyre-Spire, C; Guillouzo, A; Rogue, A; Umbdenstock, T; Vluggens, A; Weaver, RJ | 1 |
| Kim, J; Lee, H; Lim, J; Shin, SS; Yang, H; Yoon, M; Yoon, S | 1 |
1 review(s) available for oxazoles and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Evolving Role for Pharmacotherapy in NAFLD/NASH.
Topics: Adult; Benzhydryl Compounds; Chenodeoxycholic Acid; Child; Clinical Trials, Phase III as Topic; Fibroblast Growth Factors; Glucosides; Humans; Imidazoles; Isobutyrates; Liraglutide; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Oxazoles; Polyethylene Glycols; Pyridazines; Pyrimidines; Severity of Illness Index; Sulfoxides; Treatment Outcome; Uracil | 2021 |
3 trial(s) available for oxazoles and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Topics: Azetidines; Double-Blind Method; Fibrosis; Glucagon-Like Peptides; Humans; Isobutyrates; Isonicotinic Acids; Non-alcoholic Fatty Liver Disease; Oxazoles; Pyrimidines; Treatment Outcome | 2022 |
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Topics: Aged; Azetidines; Benzamides; Biomarkers; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; End Stage Liver Disease; Female; Humans; Imidazoles; Isobutyrates; Isonicotinic Acids; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxazoles; Pyridines; Pyrimidines; Severity of Illness Index; Treatment Outcome | 2021 |
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Topics: Acetyl-CoA Carboxylase; Biomarkers; Carnitine; Double-Blind Method; Elasticity Imaging Techniques; Fatty Liver; Female; Humans; Isobutyrates; Liver Cirrhosis; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxazoles; Pyrimidines | 2018 |
7 other study(ies) available for oxazoles and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.
Topics: Azetidines; Dancing; Glucagon-Like Peptides; Humans; Isobutyrates; Isonicotinic Acids; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Oxazoles; Pyrimidines | 2022 |
Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
Topics: Acetyl-CoA Carboxylase; Animals; Disease Models, Animal; Enzyme Inhibitors; Gene Knockout Techniques; Isobutyrates; Liver; Liver Cirrhosis; Mice; Non-alcoholic Fatty Liver Disease; Organ Size; Oxazoles; Pyrimidines; Receptor, Melanocortin, Type 4; Triglycerides | 2020 |
Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis.
Topics: Acetyl-CoA Carboxylase; Acyl-CoA Dehydrogenase; Animals; Cells, Cultured; Disease Models, Animal; Fatty Acids; Gene Expression Regulation, Enzymologic; Hepatocytes; Histones; Insulin Resistance; Linoleic Acids, Conjugated; Lipogenesis; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Oxazoles; Oxidation-Reduction; PPAR alpha; Signal Transduction; Transcriptional Activation; Tyrosine | 2021 |
Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α.
Topics: Animals; Choline; Diet; Lipid Metabolism; Liver; Methionine; Mice; Non-alcoholic Fatty Liver Disease; Oxazoles; PPAR alpha; Silybin; Tyrosine | 2021 |
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Topics: Acetyl-CoA Carboxylase; Administration, Oral; Adolescent; Adult; Aged; Elasticity Imaging Techniques; Enzyme Inhibitors; Female; Humans; Isobutyrates; Lipogenesis; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Oxazoles; Prospective Studies; Pyrimidines; Treatment Outcome; Young Adult | 2018 |
PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Topics: Cell Line; Constitutive Androstane Receptor; Drug Evaluation, Preclinical; Fatty Acids, Nonesterified; Fatty Liver; Gene Expression Regulation; Glycine; Humans; Lipid Metabolism; Lipogenesis; Lipotropic Agents; Liver; Liver X Receptors; Non-alcoholic Fatty Liver Disease; Oleic Acid; Orphan Nuclear Receptors; Oxazoles; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Triglycerides | 2014 |
The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Biomarkers; Cytokines; Disease Models, Animal; Fenofibrate; Gene Expression Regulation, Enzymologic; Hep G2 Cells; Hepatitis; Hepatocytes; Humans; Hypolipidemic Agents; Inflammation Mediators; Lipids; Lipogenesis; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Oxazoles; Plant Extracts; PPAR alpha; Rats, Inbred OLETF; RNA, Messenger; Transfection; Tyrosine | 2017 |